Houston Methodist Research Institut — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$10,000	1
2023	Research	$1,727,612	5
2022	Research	$1,267,199	8
2021	Research	$2,176,306	7
2020	Research	$170,094	3
2019	Research	$2,331	2

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $5,266,873 20 payments
Alexion Pharmaceuticals, Inc. $76,670 5 payments
Penumbra, Inc. $10,000 1 payment

Studies the money was for Research payments · program years 2019–2025

Multicenter Phase II Trial of Durvalumab with Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer - DTP Trial $3,995,132 7 payments
MULTICENTER PHASE I/Ib TRIAL OF OLAPARIB IN COMBINATION WITH VORINOSTAT IN PATIENTS WITH RELAPSED/REFRACTORY AND/OR METASTATIC BREAST CANCER $1,057,061 3 payments
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID 19 $144,134 2 payments
A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) $39,583 1 payment
A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) $34,818 1 payment
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy $28,898 1 payment
Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement Inhibitor Naive Adult Patients With Generalized Myasthenia Gravis $25,088 1 payment
Strike-Pe $10,000 1 payment
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry $5,138 1 payment
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies $4,362 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.